To The Moon

Abbott Laboratories, a diversified healthcare giant with a 135+ year history, has faced investor frustration in early 2026. Its stock has pulled back sharply, trading around $95–$96 as of mid-April 2026 following a roughly 6% drop after Q1 results. The primary culprit? Continued weakness in the nutrition segment, which includes household names like Similac infant formula and Ensure adult shakes. This drag has overshadowed solid growth elsewhere, raising questions about near-term recovery and whether ABT remains a compelling long-term holding.

The Nutrition Drag: What’s Happening?Abbott’s nutrition business has been a consistent underperformer. In Q4 2025, worldwide nutrition sales fell 8.9% year-over-year to $1.94 billion (9.1% organic decline), driven by U.S. market share losses—partly from the loss of a major WIC (Women, Infants, and Children) contract—plus consumer price sensitivity after post-pandemic cost inflation. Higher manufacturing expenses prompted price increases, but these backfired on volumes. Management called the path “not sustainable long-term” and began aggressive pricing and promotion adjustments late in the quarter.

The pain carried into Q1 2026. Nutrition sales declined 6.0% reported (7.7% comparable) to $2.02 billion, with pediatric nutrition down 9.7% and adult down 5.9%. CEO Robert Ford noted early progress from the Q4 pricing actions and new product launches, but acknowledged the segment remains under pressure. The company expects nutrition to stay challenged through the first half of 2026 before returning to growth in the second half, supported by at least eight new product launches over the next 12 months aimed at rebalancing price and volume.This segment (roughly 15–20% of revenue historically) has weighed on overall results and sentiment. Q4 2025 revenue missed estimates ($11.46 billion vs. ~$11.8 billion expected), triggering a double-digit single-day stock drop—the worst in over 20 years. Q1 2026 showed resilience elsewhere, but nutrition softness contributed to margin pressure and a trimmed full-year EPS outlook.

Q1 2026 Results: Beats Masked by Guidance and NutritionDespite the nutrition headwinds, Abbott delivered a solid operational quarter:Revenue: $11.16 billion (+7.8% YoY), beating consensus (~$10.99–$11.02 billion).

Adjusted EPS: $1.15 (in line with guidance of $1.12–$1.18).

Medical Devices led the way with double-digit growth, fueled by diabetes care (FreeStyle Libre CGM sales up 7.5%, with double-digit expected in Q2 and catalysts like expanded Type 2 coverage). Diagnostics normalized post-COVID, while Established Pharmaceuticals grew strongly in emerging markets. The March 2026 acquisition of Exact Sciences (closed March 23 for ~$21 billion equity / $23 billion enterprise value) adds oncology diagnostics firepower via Cologuard and Oncotype DX, contributing ~$3 billion in incremental 2026 sales and accelerating diagnostics growth.Full-year 2026 guidance: Comparable organic sales growth of 6.5%–7.5%; adjusted EPS of $5.38–$5.58 (includes $0.20 dilution from the Exact Sciences deal). This reflects a cautious nutrition reset but confidence in innovation and execution elsewhere.

Will Nutrition Recover? The Path ForwardYes—management sees a clear inflection in H2 2026. Strategic pricing is designed to rebuild volumes without sacrificing margins long-term, complemented by a robust innovation pipeline. Abbott has faced similar cyclical pressures before and emerged stronger through product refreshes and market share regain.Broader tailwinds support recovery: An aging global population drives demand for adult nutrition (Ensure), while pediatric recovery hinges on WIC dynamics and competitive positioning. Nutrition isn’t Abbott’s growth engine anymore—Medical Devices and Diagnostics now are—but stabilizing it removes a key overhang.Long-Term Investment Case: Diversified Growth with a Dividend MoatFor long-term holders, ABT offers a compelling profile beyond near-term noise:High-growth pillars: Diabetes management (FreeStyle Libre), structural heart devices, electrophysiology, and now oncology diagnostics via Exact Sciences position Abbott in secular growth areas. Devices alone have delivered consistent double-digit gains.

Diversification: Four segments (Nutrition, Diagnostics, Established Pharma, Medical Devices) reduce reliance on any one area. Post-acquisition, diagnostics gains meaningful scale in high-margin cancer screening.

Financial strength: Abbott maintains investment-grade credit, funds growth internally, and delivers steady margin expansion. 2026 guidance implies mid-single-digit revenue growth with EPS expansion despite dilution.

Shareholder returns: A Dividend Aristocrat with 51+ consecutive years of increases. Quarterly dividend recently at $0.63 (annualized ~$2.52), yielding ~2.4–2.5% at current prices. Consistent buybacks and capital allocation reinforce total returns.

Analysts largely agree. Consensus is Moderate Buy (21–29 analysts), with 12-month price targets averaging $130–$137 (implying 35–40%+ upside from ~$95–$96). Long-term models project 8%+ revenue growth, stable margins, and multiple expansion potential as nutrition stabilizes and Exact Sciences integrates.Valuation appears reasonable post-pullback (forward P/E in the low-to-mid 20s range based on guidance), especially versus historical premiums for quality healthcare names.Risks to MonitorProlonged nutrition weakness if pricing fails to spark volume or if commodity costs rise again.

Integration risks and dilution from Exact Sciences (accretive to growth and margins longer-term but EPS-dilutive through 2027).

Macro pressures: Currency, China exposure, or softer consumer spending.

Competition in CGM and diagnostics; regulatory hurdles in medtech.

Bottom Line: A Buy for Patient Long-Term InvestorsThe nutrition disappointment is real and has pressured the stock in 2026. However, it appears transient—a self-inflicted reset from pricing strategy rather than structural decline. With Medical Devices firing on all cylinders, diagnostics bolstered by a transformative acquisition, and a proven innovation track record, Abbott is positioned for accelerating growth into 2027 and beyond.At current levels, ABT offers an attractive entry for long-term portfolios seeking healthcare exposure with defensive qualities, dividend growth, and upside from innovation. The recovery thesis hinges on H2 nutrition stabilization, but the diversified engine provides downside protection. Investors with a 3–5+ year horizon should view the recent weakness as a buying opportunity rather than a red flag.